Zhijie Wu

This paper engineers an improved IgG-degrading enzyme, IdeSM33, showing enhanced activity and IgG depletion in vivo, with therapeutic potential for autoimmune diseases and gene therapy.

The paper investigates two STAT5B mutations in T cell leukemias, showing one causes gain-of-function and the other loss-of-function, with distinct impacts on immune cell populations and transcriptional activity.

This study uses single-cell multi-omics to map genotype-to-phenotype relationships in VEXAS syndrome, identifying PERK pathway activation as a therapeutic target.